Dianthus Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 16 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 127.92.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Dianthus Therapeutics Inc is 6.11, ranking 287 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 284.00K, representing a year-over-year decrease of 78.58%, while its net profit experienced a year-over-year decrease of 126.55%.
Key Metrics
The current valuation score of Dianthus Therapeutics Inc is 6.72, ranking 229 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -18.94, which is -121.90% below the recent high of 4.15 and -77.75% above the recent low of -33.66.
The current earnings forecast score of Dianthus Therapeutics Inc is 9.00, ranking 18 out of 391 in the Biotechnology & Medical Research industry. The average price target is 65.00, with a high of 100.00 and a low of 46.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Dianthus Therapeutics Inc is 9.44, ranking 10 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 94.75 and the support level at 57.73, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Dianthus Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 100.64%, representing a quarter-over-quarter decrease of 3.91%. The largest institutional shareholder is Steven Cohen, holding a total of 2.98M shares, representing 5.77% of shares outstanding, with 24.62% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dianthus Therapeutics Inc is 5.74, ranking 39 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Dianthus Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
